Protagenic Therapeutics
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Protagenic Therapeutics generated cash of -$3,703,776, which is less than the previous year. Cash used in financing activities reached the amount of $0 last year. Net change in cash is therefore $1,072,704.
Cash Flow
| 2014 | -790K | -1K | 175K |
|---|---|---|---|
| 2015 | -378K | -1K | 340K |
| 2016 | -1.14M | 0 | 4.28M |
| 2017 | -1.38M | -1.28M | 0 |
| 2018 | -1.07M | 1.04M | 0 |
| 2019 | -487.99K | 250K | 670K |
| 2020 | -1.34M | 0 | 1.22M |
| 2021 | -2.79M | -9.90M | 12.57M |
| 2022 | -1.99M | 1.59M | 0 |
| 2023 | -3.70M | 4.77M | 0 |
PTIX Cash Flow Statement (2014 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 215.18K | 541.17K | 671.09K | 798.62K | 362.48K | 399.68K | 3.10M | 3.34K | 101K | 717K |
Operating activities | ||||||||||
Net income | -5.00M | -3.55M | -4.52M | -2.54M | -1.75M | -2.55M | -2.25M | -2.27M | -476K | -1.07M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 28.21K | 30 | 427.13K | 286 | 339 | 347 | 148 | 534 | 1K | 0 |
Stock-based compensation expense | 666.82K | 864.68K | 1.51M | 1.65M | 797.76K | 0 | 888.28K | 546.13K | 478 | 275K |
| Deferred income tax benefit | 666.82K | 864.68K | 1.51M | 1.65M | 797.76K | 0 | 888.28K | 546.13K | 478 | 275K |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 6 | 0 | 308K |
Inventories | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -308K |
Accounts payable | -27.32K | -91.59K | 340.12K | 0 | 99.54K | 98.58K | 17.25K | 52.25K | 30K | -33K |
Cash generated by operating activities | -3.70M | -1.99M | -2.79M | -1.34M | -487.99K | -1.07M | -1.38M | -1.14M | -378K | -790K |
Investing activities | ||||||||||
Purchases Of Investments | -2.76M | -34.12K | -10.39M | 0 | 0 | -2.74M | -3.43M | 0 | 0 | 0 |
Investments In Property Plant And Equipment | -149.77K | -1.80K | 0 | 0 | 0 | 0 | 0 | 0 | -1K | -1K |
Acquisitions Net | 0 | 46.05K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash generated by investing activities | 4.77M | 1.59M | -9.90M | 0 | 250K | 1.04M | -1.28M | 0 | -1K | -1K |
Financing activities | ||||||||||
Common Stock Issued | 0 | 0 | 11.70M | 0 | 0 | 0 | 0 | 150K | 340K | 0 |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 0 | 0 | -100K | -1.22M | 670K | 0 | 0 | -19K | 340K | -175K |
Cash used in financing activities | 0 | 0 | 12.57M | 1.22M | 670K | 0 | 0 | 4.28M | 340K | 175K |
Net Change In Cash | 1.07M | -325.98K | -129.92K | -127.53K | 436.13K | -37.20K | -2.70M | 3.09M | -39K | -616K |
Cash at end of period | 1.28M | 215.18K | 541.17K | 671.09K | 798.62K | 362.48K | 399.68K | 3.10M | 62K | 101K |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |